0001593984 2025-01-01 2025-12-31 0001593984 2025-04-01 2025-06-30 0001593984 2026-04-01 2026-06-30 0001593984 2025-01-01 2025-06-30 0001593984 2026-01-01 2026-06-30 0001593984 2024-12-31 0001593984 2026-03-31 0001593984 2025-12-31 0001593984 2025-06-30 0001593984 2026-06-30 0001593984 2025-03-31 0001593984 mdwd:SeriesAWarrantsMember mdwd:SubsequentsEventMember 2026-07-31 0001593984 mdwd:SeriesAWarrantsMember mdwd:SubsequentsEventMember 2026-08-31 0001593984 mdwd:SeriesAWarrantsMember mdwd:SubsequentsEventMember 2026-07-01 2026-07-31 0001593984 mdwd:SeriesAWarrantsMember mdwd:SubsequentsEventMember 2026-08-01 2026-08-31 0001593984 mdwd:BardaMember 2026-04-30 0001593984 mdwd:EmployeesOfficersBoardMembersMember mdwd:SubsequentsEventMember 2026-08-01 2026-08-12 0001593984 mdwd:EmployeesOfficersBoardMembersMember ifrs-full:ShareOptionsMember 2026-03-04 2026-03-04 0001593984 mdwd:EmployeesOfficersBoardMembersMember ifrs-full:ShareOptionsMember 2026-03-04 0001593984 mdwd:EmployeesOfficersBoardMembersMember mdwd:RestrictedSharesUnitsMember 2026-03-04 2026-03-04 0001593984 mdwd:SeriesAWarrantsMember 2026-05-25 2026-05-25 0001593984 mdwd:BlackAndScholesModelMember 2026-05-25 2026-05-25 0001593984 mdwd:BlackAndScholesModelMember 2025-12-31 0001593984 mdwd:BlackAndScholesModelMember 2024-12-31 0001593984 mdwd:BlackAndScholesModelMember 2025-06-30 0001593984 mdwd:BlackAndScholesModelMember 2026-06-30 0001593984 mdwd:BlackAndScholesModelMember 2025-01-01 2025-12-31 0001593984 mdwd:BlackAndScholesModelMember 2025-01-01 2025-06-30 0001593984 mdwd:BlackAndScholesModelMember 2026-01-01 2026-06-30 0001593984 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2026-04-01 2026-06-30 0001593984 ifrs-full:SharePremiumMember 2026-04-01 2026-06-30 0001593984 ifrs-full:IssuedCapitalMember 2026-04-01 2026-06-30 0001593984 ifrs-full:RetainedEarningsMember 2026-04-01 2026-06-30 0001593984 ifrs-full:RetainedEarningsMember 2026-06-30 0001593984 ifrs-full:SharePremiumMember 2026-06-30 0001593984 ifrs-full:IssuedCapitalMember 2026-06-30 0001593984 ifrs-full:RetainedEarningsMember 2025-03-31 0001593984 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2025-03-31 0001593984 ifrs-full:SharePremiumMember 2025-03-31 0001593984 ifrs-full:RetainedEarningsMember 2025-04-01 2025-06-30 0001593984 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2025-04-01 2025-06-30 0001593984 ifrs-full:SharePremiumMember 2025-04-01 2025-06-30 0001593984 ifrs-full:IssuedCapitalMember 2025-04-01 2025-06-30 0001593984 ifrs-full:RetainedEarningsMember 2025-06-30 0001593984 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2025-06-30 0001593984 ifrs-full:SharePremiumMember 2025-06-30 0001593984 ifrs-full:IssuedCapitalMember 2025-06-30 0001593984 ifrs-full:RetainedEarningsMember 2026-01-01 2026-06-30 0001593984 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2026-01-01 2026-06-30 0001593984 ifrs-full:SharePremiumMember 2026-01-01 2026-06-30 0001593984 ifrs-full:IssuedCapitalMember 2026-01-01 2026-06-30 0001593984 ifrs-full:SharePremiumMember 2025-12-31 0001593984 ifrs-full:IssuedCapitalMember 2025-12-31 0001593984 ifrs-full:RetainedEarningsMember 2025-01-01 2025-06-30 0001593984 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2025-01-01 2025-06-30 0001593984 ifrs-full:SharePremiumMember 2025-01-01 2025-06-30 0001593984 ifrs-full:IssuedCapitalMember 2025-01-01 2025-06-30 0001593984 ifrs-full:RetainedEarningsMember 2025-01-01 2025-12-31 0001593984 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2025-01-01 2025-12-31 0001593984 ifrs-full:SharePremiumMember 2025-01-01 2025-12-31 0001593984 ifrs-full:IssuedCapitalMember 2025-01-01 2025-12-31 0001593984 ifrs-full:RetainedEarningsMember 2024-12-31 0001593984 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2024-12-31 0001593984 ifrs-full:SharePremiumMember 2024-12-31 0001593984 ifrs-full:IssuedCapitalMember 2024-12-31 0001593984 ifrs-full:RetainedEarningsMember 2025-12-31 0001593984 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2025-12-31 0001593984 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2026-06-30 0001593984 ifrs-full:IssuedCapitalMember 2025-03-31 0001593984 ifrs-full:RetainedEarningsMember 2026-03-31 0001593984 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2026-03-31 0001593984 ifrs-full:SharePremiumMember 2026-03-31 0001593984 ifrs-full:IssuedCapitalMember 2026-03-31 0001593984 mdwd:USDepartmentOfDefenseMember 2022-02-17 0001593984 mdwd:BardaMember 2025-09-01 2025-09-30 0001593984 mdwd:BardaMember 2025-12-31 0001593984 mdwd:BardaMember 2025-01-01 2025-12-31 0001593984 mdwd:USDepartmentOfDefenseMember 2023-12-31 0001593984 mdwd:USDepartmentOfDefenseMember 2024-05-31 0001593984 mdwd:USDepartmentOfDefenseMember 2026-06-30 0001593984 mdwd:USDepartmentOfDefenseMember 2025-04-30 0001593984 mdwd:BardaMember 2023-05-31 0001593984 2023-05-31 0001593984 mdwd:USDepartmentOfDefenseMember 2025-07-31 iso4217:ILS shares pure shares iso4217:USD iso4217:USD shares 0001593984 Q2 2026 false --12-31 2026-06-30 6-K 001-36349 MediWound Ltd. 42 Hayarkon Street Yavne 8122745 IL

4344000

1059000

4799000

30997000

31377000

48341000

1689000

5012000

1621000

4117000

3843000

4093000

1804000

1788000

1110000

42951000

43079000

59964000

88000

37000

28000

449000

453000

439000

21356000

15724000

18640000

7035000

7642000

7151000

66000

33000

28928000

23922000

26291000

71879000

67001000

86255000

932000

822000

870000

4736000

18992000

12659000

7626000

5880000

7648000

5249000

3377000

4531000

18543000

29071000

25708000

0 758000 0

8784000

8504000

8291000

8605000 8070000 8152000

303000

479000

472000

17692000

17811000

16915000

36235000

46882000

42623000

0.07

20000000

12910278

12835185

10875631

260000

216000

258000

274674000

239014000

272331000

-21000

-32000

-239269000

-219090000

-228925000

35644000

20119000

43632000

71879000

67001000

86255000

3139000

3162000

2611000

1754000

5769000

1229000

6314000

371000

3874000

10800000

199000

187000

110000

80000

390000

4567000

9663000

3092000

5708000

16959000

2848000

2412000

2414000

1302000

4727000

1047000

5156000

333000

3056000

8946000

12000 15000 8000 8000 32000

3907000

7583000

2755000

4366000

13705000

660000

2080000

337000

1342000

3254000

11086000

6377000

5901000

3491000

14320000

2849000

2749000

1592000

1462000

5765000

4602000

3891000

2302000

2105000

8448000

439000

-4000

13000

18098000

13021000

9795000

7058000

28520000

-17438000

-10941000

-9458000

-5716000

-25266000

8692000

925000

3220000

429000

4017000

1582000

3985000

1121000

7993000

2461000

7110000 -3060000 2099000 -7564000 1556000

-10328000

-14001000

-7359000

-13280000

-23710000

16000

43000

33000

38000

169000

-10344000

-14044000

-7392000

-13318000

-23879000

11000

-10000

5000

-11000

-21000

-10333000

-14054000

-7387000

-13329000

-23900000

-0.8

-1.3

-0.57

-1.23

-2.1

-1.36

-1.3

-0.77

-1.23

-2.1

12861870

10816990

12883835

10835251

11376571

13261930

10816990

13206306

10835251

11376571

258000

273069000

-26000

-231877000

41424000

-7392000

5000

-7392000

-7387000

2000

850000

852000

755000

260000

274674000

-21000

-239269000

35644000

215000

236839000

-10000

-205772000

31272000

-13318000

-11000

-13318000

-13329000

1000

1313000

1314000

862000

216000

239014000

-21000

-219090000

20119000

258000

272331000

-32000

-228925000

43632000

-10344000

11000

-10344000

-10333000

2000

944000

946000

1399000

260000

274674000

-21000

-239269000

35644000

215000

235995000

-11000

-205046000

31153000

-14044000

-10000

-14044000

-14054000

1000

1313000

1314000

1706000

216000

239014000

-21000

-219090000

20119000

215000

235995000

-11000

-205046000

31153000

-23879000

-21000

-23879000

-23900000

6000

5899000

5905000

37000

27329000

27366000

3108000

258000

272331000

-32000

-228925000

43632000

-10344000

-14044000

-7392000

-13318000

-23879000

780000

752000

402000

394000

1860000

1399000

1706000

755000

862000

3108000

7747000 -2377000 2811000 -6647000 2158000 -539000 -446000 -305000 -203000 -380000 960000 943000 725000 938000 1725000

-147000

75000

9000

48000

31000

4000

-13000

925000

942000

391000

424000

1891000

91000

21000

107000

6000

51000

-5232000

5340000

-1113000

8662000

2991000

-83000

-217000

-478000

-1671000

3211000

-31000

-1151000

655000

-263000

-1363000

-1300000

-341000

-567000

37000

1665000

-151000

691000

37000

794000

2350000

724000 0 0 0 0 536000 -144000 -269000 3000 -1096000 -305000 -1162000 -622000 -1100000 4767000

-15881000

-9866000

-9127000

-5756000

-16121000

2894000

2008000

1074000

1049000

5505000

659000

585000

83000

319000

1591000

17600000

2985000

-1400000

5635000

-14036000

15365000

1562000

-2391000

4905000

-17950000

702000

537000

365000

289000

1212000

767000

838000

767000

838000

3630000

0 0 0 0 -27416000 84000 114000 0 0 214000

-19000

187000

402000

549000

29620000

80000

21000

109000

2000

95000

-455000

-8096000

-11007000

-300000

-4356000

4799000

9155000

15351000

1359000

9155000

4344000

1059000

4344000

1059000

4799000

208000

1254000

81000

1080000

1433000

-395000 -249000 -169000 -91000 -268000

<div> Note 1: General <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt"></td> <td style="width:20pt">a.</td> <td style="text-align:justify">Description of the Company and its operations: </td> </tr> </table> MediWound Ltd. was incorporated in Israel in January 2000. The Company which is located in Yavne, Israel (the "Company" or "MediWound"), is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic, non-surgical solutions for tissue repair and regeneration. The Company’s strategy leverages its breakthrough enzymatic technology platform into a diversified portfolio of biotherapeutics across multiple indications to pioneer solutions for unmet medical needs. The Company’s current portfolio is focused on next-generation protein-based therapies for burn care, wound care and tissue repair. The Company's first innovative biopharmaceutical product, NexoBrid, has received in December 2022, an approval from the U.S. Food and Drug Administration (“FDA”) and marketing approval in each country of India, Switzerland and Japan. In addition, it has a marketing authorization from the European Medicines Agency (“EMA”) and regulatory agencies in other international markets for removal of dead or damaged tissue, known as eschar, in adults with deep partial and/or full-thickness thermal burns. The Company commercializes NexoBrid globally through multiple sales channels. The Company sells NexoBrid to burn centers in the European Union, United Kingdom and Israel, primarily through its commercial organizations. The Company has established local distribution channels in multiple international markets, including Asia Pacific, EMEA, CEE and LATAM, which local distributors are also responsible for obtaining local marketing authorization within the relevant territories. In the United States, the Company entered into exclusive license and supply agreements with Vericel Corporation (“Vericel”) to commercialize NexoBrid in North America. On September 21, 2023, the Company announced the U.S. commercial availability of NexoBrid for the removal of eschar in adults with deep partial and/or full-thickness thermal burns. In August 2024, the Company announced that the FDA has approved a pediatric indication for NexoBrid allowing for eschar removal in pediatric patients aged newborn through eighteen with deep partial and/or full-thickness thermal burns. With this FDA approval, NexoBrid is now authorized for use in the U.S. for all age groups, aligning with its approvals in the European Union and Japan. The Company’s second investigational next-generation enzymatic therapy product, EscharEx, is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds. In February 2025, the Company announced the initiation of VALUE, a global, pivotal Phase III trial evaluating EscharEx for the treatment of venous leg ulcers (VLUs). <div style="margin-top:0pt;margin-bottom:0pt"></div> <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt;text-align:right"></td> <td style="width:20pt">b.</td> <td>The Company's securities are listed for trading on NASDAQ since March 2014.</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt"></td> <td style="width:20pt">c.</td> <td style="text-align:justify">The Company has three wholly owned subsidiaries: MediWound Germany GmbH, acting as Europe (“EU”) marketing authorization holder and EU sales and marketing arm, MediWound UK Limited and MediWound US, Inc. which are currently inactive companies.</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt"></td> <td style="width:20pt">d.</td> <td style="text-align:justify">BARDA Contracts:</td> </tr> </table> In September 2015, the Company was awarded a Biomedical Advanced Research and Developments Authority (“BARDA”) contract for treatment of thermal burn injuries. This contract was amended multiple times to extend its term until September 2025 and its total value, up to a total amount of $165,000 as of the end of 2022. In May 2023, BARDA has awarded an additional approximately $10,000 to the Company. The total amount of the contract is comprised of $110,000 to support research and development activities and up to $65,000 to procure Nexobrid for U.S. emergency preparedness (which will be split between the Company and Vericel following Vericel’s agreement). As of December 31, 2025, the Company has recognized approximately $99,809 in the aggregate, from BARDA for support of its research and development activities and an additional $16,500 for procurement of Nexobrid for U.S. emergency preparedness, which were recorded at the net amount of approximately $10,500 following the split of gross profit agreement with Vericel for the initial BARDA procurement. The contract expired in September 2025. (See also note 4.2) <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt"></td> <td style="width:20pt">e.</td> <td style="text-align:justify">DOW and MTEC contracts:</td> </tr> </table> On February 17, 2022, the Company entered into a contract with the U.S. Department of War (DOW), through the Medical Technology Enterprise Consortium (MTEC), to develop NexoBrid as a non-surgical solution for field-care burn treatment for the U.S. Army. The contract provides funding up to $2,727. During 2023, the DOW through MTEC awarded the Company additional funding of $9,117. In addition, the Company was awarded directly through MTEC funding of $1,190, to advance the development of a new temperature stable formulation of NexoBrid. In May 2024 the Company was awarded additional funding of $1,557 from the DOW through MTEC. In April 2025 the Company was awarded additional funding of $937 from the DOW through MTEC. In July 2025 the Company was awarded additional funding of $2,715 from the DOW through MTEC. The total funding from the DOW and MTEC is $18,243. <div style="margin-top:0pt;margin-bottom:0pt"></div> <div> <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt"></td> <td style="width:20pt">f.</td> <td style="text-align:justify">The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern. From inception to June 30, 2026, the Company has incurred cash outflows from operations, losses from operations, and has an accumulated deficit of $239.3 million.</td> </tr> </table> The Company believes that its existing cash and cash equivalents, and bank deposits of $35.8 million as of June 30, 2026, will be sufficient to fund its operations and capital expenditure for at least twelve months from the date of issuance of these consolidated financial statements. <table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"> <tr style="vertical-align:top"> <td style="width:63.85pt"></td> <td style="width:18pt">g.</td> <td style="text-align:justify">In October 2023, Israel was attacked by a terrorist organization and entered a state of war. On June 13, 2025, Israel launched Operation “Rising Lion”, a direct military campaign targeting Iranian military and nuclear infrastructure in response to escalating regional security threats. A ceasefire between Israel and Iran was declared on June 24, 2025. In October 2025, a ceasefire was reached between Israel and Hamas in the Gaza Strip. On February 28, 2026, a joint military operation by the United States and Israel against Iran commenced following escalating regional tensions. In response, Iran launched ballistic missiles and unmanned aerial vehicles toward Israel. On March 1, 2026, hostilities further expanded following rocket fire from Lebanon toward Israel. On April 8, 2026, a ceasefire was announced between the United States and Iran.</td> </tr> </table> The Company's headquarters, manufacturing and R&D facilities are located in Israel. Despite these developments, the Company's operations have remained largely unaffected, and during the period ended June 30, 2026, the impact on the Company's results of operations and financial condition was not material. Nevertheless, the regional security and geopolitical environment remains sensitive and dynamic, and management continues to closely monitor developments and assess their potential impact on the Company's operations and financial condition in the future. </div> </div>

165000000 10000000 110000000 65000000 99809000 16500000

10500000

2727000 9117000 1190000 1557000 937000 2715000 18243000

-239300000

35800000

<div> Note 2: Material Accounting Policies <div> <div> <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt;text-align:right"></td> <td style="width:20pt">a.</td> <td>Basis of preparation of the interim consolidated financial statements:</td> </tr> </table> The interim condensed consolidated financial statements for the six and three months ended June 30, 2026, have been prepared in accordance with IAS 34 "Interim Financial Reporting". These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and do not include all of the information required for full annual financial statements. They should be read in conjunction with the financial statements as at and for the year ended December 31, 2025 (hereinafter – “the annual financial statements”). These condensed consolidated interim financial statements were authorized for issue by the Group’s Board of Directors on August 13, 2026. </div> </div> <div> <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt"></td> <td style="width:20pt">b.</td> <td style="text-align:justify">Use of judgements and estimates:</td> </tr> </table> In preparing these interim financial statements, management has made judgements and estimates about the future, including climate-related risks and opportunities, that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. The significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements. </div> </div>

<div> <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt;text-align:right"></td> <td style="width:20pt">a.</td> <td>Basis of preparation of the interim consolidated financial statements:</td> </tr> </table> The interim condensed consolidated financial statements for the six and three months ended June 30, 2026, have been prepared in accordance with IAS 34 "Interim Financial Reporting". These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and do not include all of the information required for full annual financial statements. They should be read in conjunction with the financial statements as at and for the year ended December 31, 2025 (hereinafter – “the annual financial statements”). These condensed consolidated interim financial statements were authorized for issue by the Group’s Board of Directors on August 13, 2026. </div> <div> <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt"></td> <td style="width:20pt">b.</td> <td style="text-align:justify">Use of judgements and estimates:</td> </tr> </table> In preparing these interim financial statements, management has made judgements and estimates about the future, including climate-related risks and opportunities, that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. The significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements. </div>

<div> Note 3: Equity <div> <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt"></td> <td style="width:20pt">1.</td> <td style="text-align:justify">On March 4, 2026, the Company’s Board of Directors approved the grant of 280,150 share options and 31,800 restricted share units (RSUs) to officers, directors and employees of the Company. The share options have an exercise price of $17.60 per share and will vest over a period of 1 to 4 years.</td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt"></div> <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt"></td> <td style="width:20pt">2.</td> <td style="text-align:justify">On May 25, 2026, 50,000 Series A warrants were exercised into the Company's ordinary shares at an exercise price of $13.475 per ordinary share, in accordance with the terms of the Series A warrant.</td> </tr> </table> The fair value of the warrants which are classified as current liabilities was measured by using the Black-Scholes model. The following inputs were used to determine the fair value: Contractual period of warrants–0.41 years. Expected volatility – 43.7% Risk-free interest rate – 3.96% Expected dividend yield – 0%. <div style="margin-left:85.5pt"> <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font:10pt Times New Roman, Times, serif;width:97%"> <tr style="vertical-align:bottom"> <td style="padding-bottom:1pt"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td colspan="6" rowspan="1" style="border-bottom:1pt solid black;font-weight:bold;text-align:center">Jun-30</td> <td style="padding-bottom:1pt;text-align:center"> </td> <td style="text-align:center;font-weight:bold;padding-bottom:1pt"> </td> <td colspan="2" rowspan="1" style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">Dec-31</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:center"> </td> </tr> <tr style="vertical-align:bottom"> <td style="text-align:center;padding-bottom:1pt"> </td> <td style="text-align:center;font-weight:bold;padding-bottom:1pt"> </td> <td colspan="2" rowspan="1" style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2026</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:center"> </td> <td style="text-align:center;font-weight:bold;padding-bottom:1pt"> </td> <td colspan="2" rowspan="1" style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2025</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:center"> </td> <td style="text-align:center;font-weight:bold;padding-bottom:1pt"> </td> <td colspan="2" rowspan="1" style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2025</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td> </td> <td> </td> <td style="text-align:left"> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> <td> </td> <td style="text-align:left"> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> <td> </td> <td style="text-align:left"> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="width:64%;text-align:justify">Balance as of January 1</td> <td style="width:1%;font-weight:bold"> </td> <td style="width:1%;font-weight:bold;text-align:left"> </td> <td style="width:9%;font-weight:bold;text-align:right">12,659</td> <td style="width:1%;font-weight:bold;text-align:left"> </td> <td style="width:1%"> </td> <td style="width:1%;text-align:left"> </td> <td style="width:9%;text-align:right">17,092</td> <td style="width:1%;text-align:left"> </td> <td style="width:1%"> </td> <td style="width:1%;text-align:left"> </td> <td style="width:9%;text-align:right">17,092</td> <td style="width:1%;text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="text-align:justify">Exercise of warrants</td> <td style="font-weight:bold"> </td> <td style="font-weight:bold;text-align:left"> </td> <td style="font-weight:bold;text-align:right">(176</td> <td style="font-weight:bold;text-align:left">)</td> <td> </td> <td style="text-align:left"> </td> <td style="text-align:right">(477</td> <td style="text-align:left">)</td> <td> </td> <td style="text-align:left"> </td> <td style="text-align:right">(2,275</td> <td style="text-align:left">)</td> </tr> <tr style="vertical-align:bottom"> <td style="text-align:justify;padding-bottom:1pt">Revaluation of warrants accounted at fair value</td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:left"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:right">(7,747</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:left">)</td> <td style="padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;text-align:left"> </td> <td style="border-bottom:Black 1pt solid;text-align:right">2,377</td> <td style="padding-bottom:1pt;text-align:left"> </td> <td style="padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;text-align:left"> </td> <td style="border-bottom:Black 1pt solid;text-align:right">(2,158</td> <td style="padding-bottom:1pt;text-align:left">)</td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="text-align:justify;padding-bottom:2.5pt">Balance at the end of the period</td> <td style="font-weight:bold;padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;font-weight:bold;text-align:left"> </td> <td style="border-bottom:Black 2.5pt double;font-weight:bold;text-align:right">4,736</td> <td style="padding-bottom:2.5pt;font-weight:bold;text-align:left"> </td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:left"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">18,992</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:left"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">12,659</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> </tr> </table> </div> </div> </div>

280150

31800

17.6

1 to 4 years

50000

13.475

P0Y4M28D 0.437 0.0396 0 <div style="margin-left:85.5pt"> <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font:10pt Times New Roman, Times, serif;width:97%"> <tr style="vertical-align:bottom"> <td style="padding-bottom:1pt"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td colspan="6" rowspan="1" style="border-bottom:1pt solid black;font-weight:bold;text-align:center">Jun-30</td> <td style="padding-bottom:1pt;text-align:center"> </td> <td style="text-align:center;font-weight:bold;padding-bottom:1pt"> </td> <td colspan="2" rowspan="1" style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">Dec-31</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:center"> </td> </tr> <tr style="vertical-align:bottom"> <td style="text-align:center;padding-bottom:1pt"> </td> <td style="text-align:center;font-weight:bold;padding-bottom:1pt"> </td> <td colspan="2" rowspan="1" style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2026</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:center"> </td> <td style="text-align:center;font-weight:bold;padding-bottom:1pt"> </td> <td colspan="2" rowspan="1" style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2025</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:center"> </td> <td style="text-align:center;font-weight:bold;padding-bottom:1pt"> </td> <td colspan="2" rowspan="1" style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2025</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td> </td> <td> </td> <td style="text-align:left"> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> <td> </td> <td style="text-align:left"> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> <td> </td> <td style="text-align:left"> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="width:64%;text-align:justify">Balance as of January 1</td> <td style="width:1%;font-weight:bold"> </td> <td style="width:1%;font-weight:bold;text-align:left"> </td> <td style="width:9%;font-weight:bold;text-align:right">12,659</td> <td style="width:1%;font-weight:bold;text-align:left"> </td> <td style="width:1%"> </td> <td style="width:1%;text-align:left"> </td> <td style="width:9%;text-align:right">17,092</td> <td style="width:1%;text-align:left"> </td> <td style="width:1%"> </td> <td style="width:1%;text-align:left"> </td> <td style="width:9%;text-align:right">17,092</td> <td style="width:1%;text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="text-align:justify">Exercise of warrants</td> <td style="font-weight:bold"> </td> <td style="font-weight:bold;text-align:left"> </td> <td style="font-weight:bold;text-align:right">(176</td> <td style="font-weight:bold;text-align:left">)</td> <td> </td> <td style="text-align:left"> </td> <td style="text-align:right">(477</td> <td style="text-align:left">)</td> <td> </td> <td style="text-align:left"> </td> <td style="text-align:right">(2,275</td> <td style="text-align:left">)</td> </tr> <tr style="vertical-align:bottom"> <td style="text-align:justify;padding-bottom:1pt">Revaluation of warrants accounted at fair value</td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:left"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:right">(7,747</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:left">)</td> <td style="padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;text-align:left"> </td> <td style="border-bottom:Black 1pt solid;text-align:right">2,377</td> <td style="padding-bottom:1pt;text-align:left"> </td> <td style="padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;text-align:left"> </td> <td style="border-bottom:Black 1pt solid;text-align:right">(2,158</td> <td style="padding-bottom:1pt;text-align:left">)</td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="text-align:justify;padding-bottom:2.5pt">Balance at the end of the period</td> <td style="font-weight:bold;padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;font-weight:bold;text-align:left"> </td> <td style="border-bottom:Black 2.5pt double;font-weight:bold;text-align:right">4,736</td> <td style="padding-bottom:2.5pt;font-weight:bold;text-align:left"> </td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:left"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">18,992</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:left"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">12,659</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> </tr> </table> </div>

12659000

17092000

-176000 -477000 -2275000 7747000 -2377000 2158000

4736000

18992000

12659000

<div> Note 4: Subsequent events <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt"></td> <td style="width:20pt">1.</td> <td style="text-align:justify">In July and August 2026, 83,487 Series A warrants were exercised into the Company's ordinary shares at an exercise price of $13.475 per ordinary share, for aggregate gross proceeds of $1,125 to the Company.</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt"></td> <td style="width:20pt">2.</td> <td style="text-align:justify">In April 2026, Vericel was awarded a ten-year BARDA contract valued at up to $197 million to support NexoBrid procurement, vendor-managed inventory services, potential blast-trauma indication development, and next-generation manufacturing and formulation capabilities (The “BARDA Contract”).</td> </tr> <tr> <td style="width:65.05pt"></td> <td style="width:20pt"> </td> <td style="text-align:justify"> </td> </tr> <tr> <td style="width:65.05pt"></td> <td style="width:20pt"> </td> <td style="text-align:justify"> In connection with the “BARDA Contract” the Company and Vericel entered into a Master Services Agreement (the “MSA”), in August 2026, covering NexoBrid and next-generation product development activities. Under the MSA, the Company expects to begin recognizing revenue in the second half of 2026 by participating in a next generation development program that has been initiated to support the potential expansion of NexoBrid for use in blast- and friction-related injuries, leveraging real-world evidence. </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"> <tr style="vertical-align:top"> <td style="width:65.05pt"> </td> <td style="width:20pt">3.</td> <td style="text-align:justify">On August 12, 2026, the Company’s Board of Directors approved the grant of 4,000 share options to a service provider.</td> </tr> </table> </div>

83487 83487 13.475 13.475

1125000

197000000

4000